Search
Displaying 1–10 of 15 for “reneuron”
-
Encouraging Vision Improvements Reported in ReNeuron's Cell-Therapy Clinical Trial
Research NewsReNeuron, a cellular therapy developer in the UK, has reported vision improvements in the treated eyes of the first three retinitis pigmentosa (RP) patients in the Phase II part of the Phase I/II clinical trial for its proprietary human retinal progenitor cells (hRPC). The Phase I portion of the trial, completed last year, primarily assessed safety in subjects with minimal remaining vision.
-
ARVO 2019 Highlight: RP Patients in ReNeuron’s Cell Therapy Trial Show Further Vision Improvements
Research NewsThe latest ReNeuron results were presented at the sixth annual Retinal Cell and Gene Therapy Innovation Summit held on April 26 in Vancouver, Canada.
-
ReNeuron Reports Interim Results for Eight Patients with RP in Phase 2a Trial for Stem Cell Therapy
Research NewsThe Foundation funded earlier lab studies that made the clinical trial possible.
-
ReNeuron Not Continuing Clinical Development of Cell-Based Therapy for RP
Research NewsCompany seeks to out-license its retinal progenitor therapy to a partner
-
ARVO 2024 Highlight: InGel’s Cell Therapy Shows Promise for Preserving Vision
Research NewsThe emerging treatment is designed to work for people with RP and other conditions regardless of the gene mutation causing disease
-
FDA Authorizes Stem Cell Clinical Trial for RP in Los Angeles
Research NewsPhase 1/2a human study will evaluate neural progenitors for preserving vision
-
UCI Stem-Cell Pioneer Poised to Launch Clinical Trial for RP Patients
Research NewsDr. Henry Klassen’s progenitor-based therapy has the potential to rescue a variety of retinal cells — including rods, cones, retinal pigment epithelium and ganglion cells — and, therefore, may save vision in people with a wide range of conditions.
-
Summary of the Eighth Annual Retinal Cell & Gene Therapy Innovation Summit 2023
Research NewsThe Retinal Cell and Gene Therapy Innovation Summit has emerged as one of the most essential events for researchers and companies developing treatments and cures for retinal degenerative diseases. In its eighth year, the Innovation Summit featured 30 presentations from retina experts from around the world with more than 300 people in attendance.
-
The VISIONS Team is working hard to secure some of the world’s best researchers and clinicians in the field of retinal diseases to speak at VISIONS2018.
-
A regularly-updated table of inherited retinal diseases and dry AMD clinical trials
.png)
